Mercy Hematology and Oncology Associates Inc
Welcome,         Profile    Billing    Logout  
 549 Trials 
257 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Contact, Site Public
NCT05371028: A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada

Recruiting
N/A
100
Canada
Non-interventional Study
Takeda
Short Bowel Syndrome (SBS)
07/24
07/24
NCT05106764: Early Detection of Fabry Disease

Active, not recruiting
N/A
50
Europe
No intervention
Takeda
Fabry Disease
04/24
04/24
NCT04861233: A Study of Lubiprostone to Treat Constipation

Recruiting
N/A
3000
RoW
No Intervention
Jeil Pharmaceutical Co., Ltd.
Constipation
05/24
11/24
NCT04872491: A Study of Vedolizumab in Adults in Real-World Practice

Active, not recruiting
N/A
500
RoW
Takeda
Colitis, Ulcerative, Crohn Disease
07/24
07/24
DRALEGA, NCT05982717: A Study to Gather Information About Overall Occurrence and New Cases of Dravet and Lennox-Gastaut Syndromes in Children, Teenagers and Adults in Spain

Recruiting
N/A
250
Europe
No intervention
Takeda
Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS)
05/24
05/24
NCT04840680: A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM)

Recruiting
N/A
165
RoW
No Intervention
Takeda
Multiple Myeloma
06/24
06/24
NCT05886478: A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab Vedotin

Recruiting
N/A
50
Europe
No intervention
Takeda
T-Cell Lymphoma
06/24
06/24
mECHromatic, NCT05755568: A Study to Learn About Metachromatic Leukodystrophy (MLD) in Children in Spain

Withdrawn
N/A
30
Europe
No Intervention
Takeda
Metachromatic Leukodystrophy (MLD)
07/24
07/24
NCT06346899: A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China

Not yet recruiting
N/A
130
RoW
No intervention
Takeda
Hereditary Angioedema (HAE)
08/25
08/25
ENABLE, NCT04130191: A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II

Active, not recruiting
N/A
140
Europe, RoW
Shire, Takeda Development Center Americas, Inc.
Hereditary Angioedema (HAE)
09/24
09/24
LANDSCAPE, NCT04943796: A Study to Learn About the Occurrence of ADHD in Adults With Mental Conditions and Their Quality of Life

Recruiting
N/A
576
Europe, Canada
Takeda
Attention Deficit Hyperactivity Disorder (ADHD)
09/24
09/24
INFINITE, NCT04328662: A Study of Ninlaro in Real World Clinical Practice in China

Active, not recruiting
N/A
482
RoW
Takeda
Multiple Myeloma, Neoplasms, Plasma Cell
09/25
09/25
NCT06104878: A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Treated With Brentuximab Vedotin Together With Chemotherapy Compared to Chemotherapy Alone

Withdrawn
N/A
200
RoW
No Intervention
Takeda
Hodgkin Lymphoma
10/24
10/24
ELEGANT, NCT05737849: A Study to Learn About the Tests Looking for a Gene Mutation in Adults With Lung Cancer in China

Withdrawn
N/A
10800
RoW
No Intervention
Takeda
Non-small Cell Lung Cancer (NSCLC)
12/24
12/24
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma

Recruiting
N/A
1000
RoW
No Intervention
Takeda
Lymphoma
01/25
01/25
SUNRISE, NCT05192863: A Study of Vedolizumab in Adults With Crohn's Disease (CD)

Active, not recruiting
N/A
72
Europe, Canada, RoW
No Intervention
Takeda
Crohn's Disease
01/25
01/25
PEDS, NCT04721366: A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Young Children With Gaucher Disease

Completed
N/A
11
US
Standard of Care, SOC
Takeda
Gaucher Disease
04/23
04/23
NCT05626088: A Study in Adults With Inflammatory Bowel Disease (IBD) Receiving Vedolizumab in the Patient Support Program (PSP) in Brazil

Recruiting
N/A
2160
RoW
No Intervention
Takeda
Ulcerative Colitis, Crohn's Disease
01/25
01/25
HyMMy, NCT05879757: Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency

Recruiting
N/A
100
Europe, RoW
No Intervention
Takeda
Multiple Myeloma, Secondary Immunodeficiency (SID)
07/25
03/26
LEADER, NCT04985643: A Study of Real Life Treatment for Multiple Myeloma (MM)

Recruiting
N/A
111
RoW
Takeda
Multiple Myeloma
08/25
08/25
VARIETY, NCT05384080: A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Poland

Active, not recruiting
N/A
165
Europe
Takeda
Inflammatory Bowel Disease (IBD), Crohn's Disease, Ulcerative Colitis
08/25
08/25
NCT05013190: A Study of NINLARO® in Chinese Adults With Multiple Myeloma

Recruiting
N/A
320
RoW
No intervention
Takeda
Multiple Myeloma
10/25
10/25
NCT04961840: A Study to Assess Maternal and Fetal Outcomes After Taking Prucalopride During Pregnancy

Active, not recruiting
N/A
100
US
No Intervention
Takeda
Constipation, Pregnancy
12/25
12/25
NCT04799496: A Study of Kynteles Injection (Vedolizumab) in Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease or Chronic Pouchitis

Recruiting
N/A
600
RoW
Takeda
Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease
01/26
01/26
CHOPIN, NCT05147181: A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland

Recruiting
N/A
40
Europe
Takeda
Hereditary Angioedema (HAE)
03/26
03/26
NCT04869280: Post-Marketing Study of Prucalopride Safety In Pregnancy

Recruiting
N/A
616
US
No Intervention
Takeda, The Organization of Teratology Information Specialists
Chronic Idiopathic Constipation (CIC)
05/26
05/26
BV-MAZOVIA, NCT05100056: A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma

Recruiting
N/A
70
Europe
No Intervention
Takeda
Hodgkin Lymphoma
06/26
06/26
NCT04838522: A Study of Prucalopride in Breastfeeding Women With Constipation

Recruiting
N/A
12
US
No Intervention
Takeda, UC San Diego Human Milk Research Biorepository
Chronic Idiopathic Constipation (CIC)
12/26
12/26
NCT01034969: Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)

Recruiting
N/A
3000
Europe, RoW
Shire, Takeda Development Center Americas, Inc.
Hereditary Angioedema (HAE)
01/27
01/27
ENTIRETY, NCT05735327: A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
N/A
50
Europe
No intervention
Takeda
Non-small Cell Lung Cancer (NSCLC)
06/27
06/27
NCT05428345: A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea

Recruiting
N/A
600
RoW
Takeda
Ulcerative Colitis, Crohn's Disease, Inflammatory Bowel Disease (IBD)
11/27
11/27
NCT04158934: A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

Active, not recruiting
N/A
207
Europe, US, RoW
ADYNOVI/ADYNOVATE, Antihaemophilic Factor [Recombinant] PEGylated rurioctocog alfa pegol, TAK-660, BAX 855
Baxalta now part of Shire
Hemophilia A
02/30
02/30
PARADIGHM, NCT01922440: A Registry for Participants With Chronic Hypoparathyroidism

Active, not recruiting
N/A
1340
Europe, Canada, US
No intervention
Takeda, Takeda Development Center Americas, Inc.
Hypoparathyroidism
11/34
11/34
Schallenkamp, John M
UP-NEXT, NCT05329545: Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer

Terminated
3
20
Canada, US, RoW
Upifitimab rilsodotin, XMT-1536 Antibody Drug Conjugate, Placebo
Mersana Therapeutics, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
09/23
09/23
SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Recruiting
3
700
US
Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806
SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
03/25
03/28
A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Hourglass Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI
Recruiting
3
1100
Canada, US
Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20
SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP
Multiple Myeloma
07/29
07/40
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
10/24
10/24
NCT03994796: Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Recruiting
2
186
US
Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib, MRTX849
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Mirati Therapeutics Inc., Genentech, Inc., Eli Lilly and Company, Kazia Therapeutics Limited
CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
10/24
06/25
NCT04647916: Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Recruiting
2
44
US
Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU-132, RS7-SN38, Sacituzumab Govitecan-hziy, Trodelvy
SWOG Cancer Research Network, National Cancer Institute (NCI), Gilead Sciences
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
02/25
12/26
Farina, Cibar M Benitez
DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Hourglass Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI
Recruiting
3
1100
Canada, US
Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20
SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP
Multiple Myeloma
07/29
07/40
Roeker, Lindsey
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Canada, Japan, US, RoW
LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
11/23
05/27
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
NCT04722172: A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL

Active, not recruiting
2
55
US
Acalabrutinib, Obinutuzumab
Memorial Sloan Kettering Cancer Center, AstraZeneca, Genentech, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
02/25
02/25
NCT04419519: Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax

Recruiting
2
80
US
Venetoclax monotherapy, Venetoclax with anti CD20 monoclonal antibody
Memorial Sloan Kettering Cancer Center, Adaptive Biotechnologies
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
05/25
05/25
NCT04447768: The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)

Active, not recruiting
2
100
US
Obinutuzumab, Venetoclax
Memorial Sloan Kettering Cancer Center, Genentech, Inc.
Chronic Lymphocytic Leukemia (CLL)
07/26
07/26
NCT05003141: PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Recruiting
1a/1b
110
US, RoW
PSB202
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, Refractory B-Cell Lymphoma, MALT Lymphoma
07/23
01/24
Sokhn, Joseph
A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Hourglass Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI
Recruiting
3
1100
Canada, US
Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20
SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP
Multiple Myeloma
07/29
07/40
Rodgers, Thomas D
realMIND, NCT04981795: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

Recruiting
N/A
100
US
Tafasitamab
Incyte Corporation, Iqvia Pty Ltd
Diffuse Large B-cell Lymphoma
10/25
08/26
Ghimire, Krishna
NCI-2019-08946, NCT04269213: CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old

Recruiting
2
12
US
Liposome-encapsulated Daunorubicin-Cytarabine, CPX-351, Cytarabine-Daunorubicin Liposome for Injection, Liposomal AraC-Daunorubicin CPX-351, Liposomal Cytarabine-Daunorubicin, Liposome-encapsulated Combination of Daunorubicin and Cytarabine, Vyxeos
Roswell Park Cancer Institute, Jazz Pharmaceuticals
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
01/25
01/25
ASC2ESCALATE, NCT05384587: Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

Recruiting
2
182
US
asciminib, ABL001
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia - Chronic Phase
02/26
02/27
NCT04009109: Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

Active, not recruiting
2
79
US
Lenalidomide, Revlimid, Ixazomib, Ninlaro, Daratumumab Injection, Darzalex, Dexamethasone, Ozurdex
Alliance Foundation Trials, LLC., Janssen Scientific Affairs, LLC, Celgene Corporation, Takeda
Myeloma, Multiple
10/25
07/26
Duffy, Steven M
A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
AFT-57, NCT05798663: Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC

Recruiting
2
178
US
Atezolizumab, Tecentriq, L01XC32, Tiragolumab
Alliance Foundation Trials, LLC., Genentech, Inc.
NSCLC
08/25
10/27
NCT05585320: A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors

Recruiting
1/2
210
US
IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104, IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + mGnP, IMM-1-104 + modified FOLFIRINOX (Treatment Group C), IMM-1-104 + mFFX
Immuneering Corporation
Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)
06/26
06/27
 

Download Options